Doctor of Osteopathy Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Mark Bickert

Facial Plastic Surgery Melbourne, FL Doctor of Osteopathy

NPI 1528012242 CMS profile 1004616

1223 Gateway Dr Ste 1G, Melbourne, FL 32901

Open in the dashboard

General payments

$275

10 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Mark Bickert of Melbourne, FL is reported in the CMS Open Payments database as having received $275 across 10 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 18th percentile of Facial Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $117 2
2022 General $51 3
2021 General $55 2
2020 General $28 2
2019 General $24 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Bickert
  • Facial Plastic Surgery median
  • Middle half of Facial Plastic Surgery
  • National median

In program year 2025, general payments to Mark Bickert were reported at $0. Among 437 Facial Plastic Surgery profiles paid that year, the median was $270 and the middle half received between $116 and $579.

Show as a table
Year Mark Bickert Facial Plastic Surgery median Middle half National median
2019 $24 $225 $92–$651 $163
2020 $28 $132 $45–$323 $114
2021 $55 $186 $67–$558 $132
2022 $51 $218 $83–$594 $149
2023 $117 $237 $94–$564 $160
2024 $0 $233 $104–$575 $164
2025 $0 $270 $116–$579 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Inspire Medical Systems, Inc. $117 2 payments
  2. Genzyme Corporation $48 2 payments
  3. Acclarent, Inc $31 1 payment
  4. Smith+Nephew, Inc. $28 2 payments
  5. Checkpoint Surgical, Inc $20 1 payment
  6. Phadia US Inc. $17 1 payment
  7. Regeneron Healthcare Solutions, Inc. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $275 10 payments
Products named General payments · program years 2019–2023
  1. INSPIRE $117 2 payments
  2. Relieva Spinplus $31 1 payment
  3. DUPIXENT Immunology $25 1 payment
  4. DUPIXENT Immunology $24 1 payment
  5. Checkpoint Stimulators $20 1 payment
  6. ImmunoCAP $17 1 payment
  7. REFLEX ULTRA Turbinate Wands $16 1 payment
  8. DUPIXENT Inflammation And Immunology $15 1 payment
  9. WEREWOLF $12 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

1,256

Median for Otolaryngology: 297

Drug cost

$35,306

Median for Otolaryngology: $6,314

Branded share of claims

10%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciprofloxacin-Dexamethasone Ciprofloxacin Hcl/Dexameth Brand 85 $11,906
Famotidine Generic 276 $5,232
Ipratropium Bromide Generic 144 $4,539
Pantoprazole Sodium Generic 189 $3,266
Azelastine Hcl Generic 76 $2,366
Fluocinolone Acetonide Oil Generic 56 $2,103
Fluticasone Propionate Generic 36 $827
Cefdinir Generic 33 $644
Mometasone Furoate Generic 11 $541
Acyclovir Generic 21 $533

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 73 billing codes

Paid by Medicare

$114,370

Medicare's payments for the services billed

Medicare patients

531

Average age 74

Services billed

1,343

291 women, 240 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 29%
Ischemic heart disease 29%
Chronic kidney disease 27%
Depression 23%
COPD 22%
Osteoporosis 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

10 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Facial Plastic Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record